Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Therapeutic area

Endocrine disorders – page 33

  • 504 clinical trials
  • 189 recruiting
  • 213 conditions
  • 25 countries

Conditions in this area

213 conditions with trials, the busiest first

Type 2 diabetes mellitus85Type 1 diabetes mellitus41Endocrine ophthalmopathy26Neuroblastoma26Obesity24Diabetes mellitus21Neuroendocrine tumour19Overweight18Gastroenteropancreatic neuroendocrine tumour disease16Diabetic neuropathy13Diabetic retinal oedema13Diabetic foot12Myotonic dystrophy12Adrenogenital syndrome11Neuroendocrine carcinoma11Thyroid cancer11Graves' disease10Hypoparathyroidism9Acromegaly8Adrenoleukodystrophy8Chronic kidney disease8Glucose tolerance impaired7Pancreatic neuroendocrine tumour7Adrenocortical carcinoma6+189

Clinical trials in Endocrine disorders

504 trials across Europe, recruiting first

Type of trial
Recruitment status
Quick filters

504 clinical trials

Hyperadrenocorticism

Not recruiting

Study of SPI-62 for Treating Cushing's Syndrome in Patients with Benign Adrenal Tumors

InvestigationalNo placebo
Countries:RomaniaRomania
  • Participants:18–64 years · 65+ years
  • Substances:4-{5-[2-(4-Chloro-2,6-Difluorophenoxy)Propan-2-Yl]-4-Methyl-4H-1,2,4-Triazol-3-Yl}-3-Fluorobenzamide
  • Sponsor:Sparrow Pharmaceuticals Inc.

Neuroendocrine tumour

Not recruiting

Study on Long-term Safety of Satoreotide Tetraxetan Lutetium-177 for Patients with Somatostatin Receptor Positive Neuroendocrine Tumors

InvestigationalNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Satoreotide Tetraxetan
  • Sponsor:Ariceum Therapeutics GmbH

Pituitary-dependent Cushing's syndrome

Not recruiting

Study of Osilodrostat for Children and Adolescents with Cushing's Disease

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:0–17 years
  • Substances:Osilodrostat
  • Sponsor:Recordati AG

Neuropathic arthropathy+1

Not recruiting

Study on Denosumab for Healing Bone Fractures in Diabetic Patients with Charcot Foot

Registered drug
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Denosumab
  • Sponsor:Amsterdam UMC Stichting

Type 1 diabetes mellitus

Not recruiting

Study on the Effects of Verapamil Hydrochloride for Adults with Type 1 Diabetes to Preserve Beta-Cell Function

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years
  • Substances:Verapamil Hydrochloride
  • Sponsor:Medical University Of Graz

Type 1 diabetes mellitus

Not recruiting

Study on the Safety and Effectiveness of ProTrans for Treating Type 1 Diabetes in Children and Adolescents

InvestigationalNo placebo
Countries:SwedenSweden
  • Participants:0–17 years
  • Substances:Protrans
  • Sponsor:Region Uppsala

Type 2 diabetes mellitus

Not recruiting

Study on the Safety and Effectiveness of Metformin Hydrochloride, Dapagliflozin, and Canagliflozin in Elderly Patients with Type 2 Diabetes

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:65+ years
  • Substances:Canagliflozin
  • Sponsor:Center For Outcomes Research And Clinical Epidemiology S.r.l.

Neuroblastoma

Not recruiting

Study on Bevacizumab with Temozolomide and Irinotecan for Children with Relapsed or Refractory Neuroblastoma

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:0–17 years
  • Substances:Bevacizumab
  • Sponsor:The University Of Birmingham

Polycystic ovarian syndrome

Not recruiting

Study on the Effects of Spironolactone, Pioglitazone, and Metformin for Adolescent Girls and Young Women with Polycystic Ovary Syndrome (PCOS)

Investigational
Countries:AustriaAustria
  • Participants:0–17 years · 18–64 years
  • Substances:Metformin
  • Sponsor:Fundacio Sant Joan De Deu

Type 2 diabetes mellitus

Not recruiting

Study on the Effects of AZD5004 and Semaglutide for Adults with Type 2 Diabetes

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:AZD5004
  • Sponsor:AstraZeneca AB

Pituitary tumour benign

Not recruiting

Study on Cabergoline for Treating Non-Functioning Pituitary Adenomas in Patients

Registered drugNo placebo
Countries:NorwayNorway
  • Participants:18–64 years · 65+ years
  • Substances:Cabergoline
  • Sponsor:St. Olavs Hospital HF

Diabetes mellitus+1

Not recruiting

Study on the Effectiveness of Oxygen Therapy for Patients with Diabetic Foot Ulcers

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Oxygen
  • Sponsor:Amsterdam UMC Stichting

Substances studied in this area

The therapies tested most often in Endocrine disorders trials.

Semaglutide48 clinical trialsDapagliflozin21 clinical trialsEmpagliflozin14 clinical trialsMetformin Hydrochloride13 clinical trialsMetformin12 clinical trialsSodium Chloride12 clinical trialsCisplatin11 clinical trialsEtoposide11 clinical trialsLutetium (177LU) oxodotreotide11 clinical trials
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.